Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2020-07-03 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
20200610_BOTHE_AGO_PV_signed.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "PROCÈS-VERBAL DE L'ASSEMBLÉE GÉNÉRALE ORDINAIRE DU 10 JUIN 2020" (Minutes of the Ordinary General Meeting of June 10, 2020). It details the composition of the meeting, the agenda (which includes approving annual accounts, remuneration, and director mandates), and the voting results ('DELIBERATIONS ET DECISIONS'). This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2020-07-03 French
Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
AGM Information Classification · 98% confidence The document is explicitly titled "Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020" and states that "Shareholders approved all resolutions" from the meeting held on June 10, 2020. This content directly relates to the outcomes of an Annual General Meeting (AGM). While it also contains an outlook confirmation, the primary focus and headline concern the AGM results. This aligns perfectly with the AGM Information (AGM-R) category, which covers presentations and materials shared during the AGM, including the results thereof.
2020-06-11 English
Bone Therapeutics annonce les résultats de son Assemblée Générale Ordinaire Annuelle et confirme ses objectifs pour l’année 2020
AGM Information Classification · 98% confidence The document is titled "Bone Therapeutics annonce les résultats de son Assemblée Générale Ordinaire Annuelle et confirme ses objectifs pour l'année 2020" (Bone Therapeutics announces the results of its Annual General Meeting and confirms its objectives for 2020). It explicitly discusses the approval of resolutions during the Annual General Meeting (AGM) held on June 10, 2020. This content directly relates to the proceedings and outcomes of the AGM. Although it also confirms future objectives (which might suggest an ER or MDA), the primary focus and headline concern the AGM results. Therefore, the most appropriate classification is AGM Information (AGM-R). The document is not a short announcement linking to a report, but rather the detailed communication of the AGM results.
2020-06-11 French
PR_2020-05-28_BOTHE_Transparency Notification_SRIW_EN_Final.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement regarding a change in major shareholding (crossing the 10% threshold) by S.R.I.W. SA and Sofipôle SA in Bone Therapeutics. It explicitly references the 'Law of 2 May 2007 on disclosure of major holdings' and provides a table of voting rights before and after the transaction. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2020-05-29 English
PR_2020-05-28_BOTHE_Transparency Notification_SRIW_FR_Final.pdf
Major Shareholding Notification Classification · 100% confidence The document is a formal notification regarding a change in shareholding structure (transparency notification) where S.R.I.W. SA and Sofipôle SA crossed the 10% ownership threshold in Bone Therapeutics. This type of regulatory disclosure regarding significant shareholding changes is classified as a Major Shareholding Notification (MRQ).
2020-05-29 French
PR_2020-05-29_BOTHE_CB Denominator_EN_Final.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Information on the total number of voting rights and shares' and is dated May 29, 2020. It explicitly states that the information is published in accordance with Article 15 of the Belgian Law regarding the publication of major shareholdings. The core content details the total number of shares, voting rights, and changes due to new share issuances and convertible bond conversions. This directly relates to changes in the company's share structure and ownership reporting requirements, which aligns best with the 'Major Shareholding Notification' (MRQ) category, as it reports on the denominator (total voting rights) and related capital changes that affect major shareholding calculations. While it mentions share issuance, the primary focus is the resulting total voting rights count, making MRQ a strong fit over SHA (Share Issue/Capital Change) or DIV (Dividend Notice). It is a direct regulatory disclosure, not a general announcement (RPA/RNS).
2020-05-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.